148 related articles for article (PubMed ID: 12141950)
1. Phase III trial of a humanized anti-CD33 antibody (HuM195) in patients with relapsed or refractory acute myeloid leukemia.
Gibson AD
Clin Lymphoma; 2002 Jun; 3(1):18-9. PubMed ID: 12141950
[No Abstract] [Full Text] [Related]
2. Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT.
Swords R; Hayden PJ; Molloy K; Lawlor M; Browne PV; Murphy PT
Eur J Haematol; 2004 Dec; 73(6):450-1. PubMed ID: 15522070
[No Abstract] [Full Text] [Related]
3. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL
J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573
[TBL] [Abstract][Full Text] [Related]
4. Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
Chevallier P; Roland V; Mahé B; Juge-Morineau N; Dubruille V; Guillaume T; Vigouroux S; Moreau P; Milpied N; Garand R; Avet-Loiseau H; Harousseau JL
Leuk Res; 2005 Sep; 29(9):1003-7. PubMed ID: 16038726
[TBL] [Abstract][Full Text] [Related]
5. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
6. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia.
Cortes J; Tsimberidou AM; Alvarez R; Thomas D; Beran M; Kantarjian H; Estey E; Giles FJ
Cancer Chemother Pharmacol; 2002 Dec; 50(6):497-500. PubMed ID: 12451477
[TBL] [Abstract][Full Text] [Related]
7. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195.
Feldman E; Kalaycio M; Weiner G; Frankel S; Schulman P; Schwartzberg L; Jurcic J; Velez-Garcia E; Seiter K; Scheinberg D; Levitt D; Wedel N
Leukemia; 2003 Feb; 17(2):314-8. PubMed ID: 12592328
[TBL] [Abstract][Full Text] [Related]
8. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195.
Jurcic JG; Caron PC; Miller WH; Yao TJ; Maslak P; Finn RD; Larson SM; Warrell RP; Scheinberg DA
Leukemia; 1995 Feb; 9(2):244-8. PubMed ID: 7869759
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
[TBL] [Abstract][Full Text] [Related]
10. Acute myocardial infarction as the presenting symptom of acute myeloblastic leukemia with extreme hyperleukocytosis.
Cohen Y; Amir G; Da'as N; Gillis S; Rund D; Polliack A
Am J Hematol; 2002 Sep; 71(1):47-9. PubMed ID: 12221675
[TBL] [Abstract][Full Text] [Related]
11. [CAG-GO therapy for patients with relapsed or primary refractory CD33-positive acute myelogenous leukemia].
Takahashi W; Nakamura Y; Tadokoro J; Handa T; Arai H; Tokita K; Iso H; Tsurumi S; Sasaki K; Maki K; Mitani K
Rinsho Ketsueki; 2012 Jan; 53(1):71-7. PubMed ID: 22374527
[TBL] [Abstract][Full Text] [Related]
12. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia.
Caron PC; Dumont L; Scheinberg DA
Clin Cancer Res; 1998 Jun; 4(6):1421-8. PubMed ID: 9626458
[TBL] [Abstract][Full Text] [Related]
13. Antibody-targeted chemotherapy of relapsed AML.
Mineur P; Lejeune C; Hennaux V; Eten C
Br J Haematol; 2003 Apr; 121(1):195-6. PubMed ID: 12670356
[No Abstract] [Full Text] [Related]
14. Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial.
Raza A; Jurcic JG; Roboz GJ; Maris M; Stephenson JJ; Wood BL; Feldman EJ; Galili N; Grove LE; Drachman JG; Sievers EL
Leuk Lymphoma; 2009 Aug; 50(8):1336-44. PubMed ID: 19557623
[TBL] [Abstract][Full Text] [Related]
15. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.
Feldman EJ; Brandwein J; Stone R; Kalaycio M; Moore J; O'Connor J; Wedel N; Roboz GJ; Miller C; Chopra R; Jurcic JC; Brown R; Ehmann WC; Schulman P; Frankel SR; De Angelo D; Scheinberg D
J Clin Oncol; 2005 Jun; 23(18):4110-6. PubMed ID: 15961759
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia.
Brethon B; Auvrignon A; Galambrun C; Yakouben K; Leblanc T; Bertrand Y; Leverger G; Baruchel A
BMC Cancer; 2006 Jun; 6():172. PubMed ID: 16805911
[TBL] [Abstract][Full Text] [Related]
17. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia.
Jurcic JG; DeBlasio T; Dumont L; Yao TJ; Scheinberg DA
Clin Cancer Res; 2000 Feb; 6(2):372-80. PubMed ID: 10690513
[TBL] [Abstract][Full Text] [Related]
18. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
Tsimberidou A; Cortes J; Thomas D; Garcia-Manero G; Verstovsek S; Faderl S; Albitar M; Kantarjian H; Estey E; Giles FJ
Leuk Res; 2003 Oct; 27(10):893-7. PubMed ID: 12860008
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic advances in neoplastic hematology: target therapy anti-CD33].
Di Rocco A; Finolezzi E; Anaclerico B; Calabrese E; Levi A; Trasarti S; Tafuri A
Clin Ter; 2005; 156(4):183-6. PubMed ID: 16342520
[TBL] [Abstract][Full Text] [Related]
20. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity.
Caron PC; Jurcic JG; Scott AM; Finn RD; Divgi CR; Graham MC; Jureidini IM; Sgouros G; Tyson D; Old LJ
Blood; 1994 Apr; 83(7):1760-8. PubMed ID: 8142644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
